India's Dr. Lal PathLabs extends gains on Q1 profit beat
07/08/2024 10:56
** Shares of Dr. Lal PathLabs DLPA.NS up 3.5% at 3,283.85
rupees, its highest since January 2022
** The healthcare diagnostic firm's Q1 consol net profit
beat estimates
** Stock hit session's high post results, was up 2.4%
earlier
** Analysts' rating on avg is "buy", median PT is 2,630
rupees, per LSEG data
** Including session's gains, stock up 27% YTD
(Reporting by Manvi Pant in Bengaluru)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
Recent news on Dr. Lal PathLabs
See all newsBrief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
India's Dr Lal PathLabs rises; analysts back SN Genelab deal
Brief: Lal Pathlabs Says Subsidiary Incorporated Dr Lal Pathlabs Indomed In Tashkent, Uzbekistan
India's Dr Lal PathLabs jumps to 4-year high after quarterly profit rise